Insulin resistance represents a significant metabolic issue linked to conditions including type 2 diabetes, obesity, and metabolic syndrome. Techniques are needed to analyze glucose metabolism within tissues. 18F-FDG PET provides a noninvasive method for assessing glucose uptake and metabolism.
18F-FDG PET Methodology
Standard 18F-FDG PET relies on factors such as systemic glucose and insulin levels, tracer kinetics, and tissue characteristics, necessitating kinetic modeling for quantification. Currently, there is limited experimental data regarding the use of nano-FDG as a quantitative biomarker for insulin resistance. Research in this area primarily comes from fields like oncology, inflammation, nanoparticle design, and multimodal PET/CT and PET/MRI scans. A key limitation is the lack of validation against established metabolic benchmarks, such as the hyperinsulinemic-euglycemic clamp method.
Nanotechnology Platforms and Assessment
The review examines existing literature on 18F-FDG-based nanotechnology platforms, glucose-labeled nanoparticles, and radioactively labeled nanomaterials. It assesses the available evidence concerning the application of these technologies for evaluating nanoparticle-based therapies, considering both direct and indirect evidence related to assessing insulin resistance.